Auvelity may begin easing Alzheimer’s-related agitation within one to two weeks, but clinicians generally need several weeks to judge its benefit. In a controlled trial, improvement separated from placebo by week two, became statistically significant at week three, and was formally assessed at week five. For example, a person who paces and repeatedly shouts during evening care might have fewer episodes during the second week, yet still require observation through week five before the prescriber decides how well the treatment is working. Auvelity is not a rescue medicine for stopping an aggressive episode. It must be taken on a schedule and increased gradually according to tolerability.
Some people improve sooner than the trial average, some respond only after reaching the full dose, and others receive little benefit. New or suddenly severe agitation still requires prompt assessment for pain, infection, constipation, medication effects, delirium, or another treatable cause. The FDA approved Auvelity, a combination of dextromethorphan and bupropion, for agitation associated with dementia due to Alzheimer’s disease in adults in April 2026. It was the first approved non-antipsychotic treatment for this indication. It treats behavioral symptoms rather than the brain changes responsible for Alzheimer’s disease, so it should not be expected to restore memory or slow cognitive decline.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Quickly Can Auvelity Help Alzheimer’s Agitation?
- Auvelity’s Dosing Schedule and Expected Response
- Measuring Whether Agitation Is Actually Improving
- What Caregivers Should Do During the First Five Weeks
- Side Effects, Interactions, and Reasons Auvelity May Not Be Appropriate
- Auvelity Compared With Antipsychotic Treatment
- When Agitation Needs Immediate Evaluation Instead of a Medication Trial
- Frequently Asked Questions
How Quickly Can Auvelity Help Alzheimer’s Agitation?
The clearest evidence points to a response window measured in weeks rather than hours. In the five-week ADVANCE-1 trial, the difference between auvelity and placebo began to emerge at week two and reached statistical significance at week three, approximately one week after participants reached the target dose. At week five, the average reduction in agitation was greater with Auvelity than with placebo. The FDA-approved prescribing information describes a related five-week study in which Auvelity reduced the Cohen-Mansfield Agitation Inventory score by an adjusted average of 14.9 points, compared with 11.6 points for placebo.
The difference between the groups was 3.3 points. That placebo improvement matters: structured attention, caregiver support, regular visits, and natural fluctuations in behavior can make agitation look better even without an active drug. An open-label phase of another study recorded improvement as early as the first week, but an open-label result cannot establish that medication caused the change because everyone knew treatment was being given and there was no simultaneous placebo comparison. A caregiver may notice that bathing becomes easier after seven days, for example, but that observation should be recorded over repeated situations before it is treated as a dependable medication response.
Auvelity’s Dosing Schedule and Expected Response
For Alzheimer’s agitation, the labeled starting dose is one 30-mg/105-mg tablet in the morning. On day eight, the dose may increase to one 30-mg/105-mg tablet twice daily, at least eight hours apart, based on tolerability. On day 15, it may increase to one 45-mg/105-mg tablet twice daily. Tablets must be swallowed whole and should not be crushed, divided, or chewed. This staged schedule helps explain why a full response may not be evident during the first few days.
A person may not reach the maximum recommended dose until the third week, and dizziness or stomach upset may lead the clinician to delay an increase. Faster titration is not a safe way to force a faster response; bupropion’s seizure risk rises with dose, and excessive exposure to dextromethorphan can cause confusion, unsteadiness, or other serious effects. Auvelity should not be administered as needed during a confrontation. Giving an extra tablet when someone becomes aggressive can exceed the prescribed daily amount without providing immediate control. If a resident suddenly begins striking staff during transfers, the immediate response should involve safety, de-escalation, and assessment for an acute medical problem—not an unplanned additional dose.
Measuring Whether Agitation Is Actually Improving
Improvement should be defined through observable behavior. Useful measures include the number of pacing episodes, attempts to leave, shouted threats, repetitive calls for help, resistance during personal care, and incidents of hitting or pushing. Caregivers can record the behavior, its likely trigger, how long it lasted, and what helped. Consider a person who previously had five prolonged episodes of shouting every afternoon.
If the episodes decline to two shorter events after three weeks, while morning alertness and walking remain unchanged, that pattern may represent meaningful benefit. If shouting decreases only because the person is sleeping through most of the day, the apparent improvement may instead reflect an adverse effect or another illness. The clinical trials used the 29-item Cohen-Mansfield Agitation Inventory, which rates the frequency of verbally aggressive, physically aggressive, verbally nonaggressive, and physically nonaggressive behavior. Families do not need to calculate a formal score, but they can use the same principle: compare the same behaviors across the same settings rather than relying on a general impression after one unusually calm or difficult day.
What Caregivers Should Do During the First Five Weeks
Before treatment begins, document several days of baseline behavior and review the complete medication list with the prescriber or pharmacist. Blood pressure should be assessed, and the clinician should check for seizure risk, bipolar disorder, kidney or liver impairment, and products containing bupropion or dextromethorphan. Over-the-counter cough remedies are a practical concern because some contain dextromethorphan. During titration, record each dose along with agitation, sleep, walking stability, appetite, bowel movements, and possible adverse effects.
Scheduled reviews near the dose changes and around weeks three to five can be more informative than waiting for a crisis. For example, new wobbling that begins two days after the second daily dose is added should be reported promptly because dizziness can increase fall risk. Medication should accompany individualized dementia care. Reducing noise, maintaining a predictable routine, allowing extra time during bathing, treating pain, and avoiding confrontational correction may help with fewer adverse effects. The tradeoff is that these approaches require consistent staffing and experimentation, while medication is easier to standardize but introduces physical risks and may produce only a modest advantage over supportive care.
Side Effects, Interactions, and Reasons Auvelity May Not Be Appropriate
In the five-week placebo-controlled Alzheimer’s agitation study, dizziness and indigestion were the most common adverse reactions occurring in at least 5% of Auvelity-treated participants and at more than twice the placebo rate. Other clinically important risks include seizures, increased blood pressure, serotonin syndrome, mania or hypomania, psychosis or other neuropsychiatric reactions, angle-closure glaucoma, allergic reactions, and low blood sodium. Auvelity is contraindicated in people with a seizure disorder, a current or past diagnosis of bulimia or anorexia nervosa, or abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or antiseizure drugs. It must not be combined with a monoamine oxidase inhibitor or taken within 14 days of stopping one.
Bupropion also inhibits the CYP2D6 enzyme, so it can alter exposure to certain antidepressants, antipsychotics, beta-blockers, and other medicines. Older adults may be especially vulnerable to dizziness, confusion, blood-pressure changes, and falls. A new fall, fainting, seizure, severe headache, marked confusion, fever with muscle rigidity, or rapidly worsening behavior warrants immediate medical attention. Moderate kidney impairment, certain interacting medicines, and poor CYP2D6 metabolism can require once-daily dosing rather than the standard twice-daily maximum.
Auvelity Compared With Antipsychotic Treatment
Auvelity is a non-antipsychotic option, while brexpiprazole, sold as Rexulti, is an antipsychotic also approved for agitation associated with dementia due to Alzheimer’s disease. Auvelity’s pivotal short-term evidence assessed outcomes at five weeks; the principal brexpiprazole trials assessed agitation at 12 weeks. These timelines cannot be treated as a direct head-to-head comparison because the drugs were studied in different trials and populations.
Antipsychotics carry a boxed warning that elderly people with dementia-related psychosis have an increased risk of death. Auvelity avoids that antipsychotic-class warning but has its own boxed warning about suicidal thoughts and behaviors in pediatric and young-adult patients taking antidepressants, along with seizure and interaction concerns. For a person with uncontrolled hypertension and repeated falls, for example, the fact that Auvelity is not an antipsychotic does not automatically make it the safer choice.
When Agitation Needs Immediate Evaluation Instead of a Medication Trial
A sudden change over hours or days is less typical of a gradual Alzheimer’s behavioral pattern and can signal delirium. Common triggers include urinary or respiratory infection, dehydration, urinary retention, constipation, uncontrolled pain, sleep disruption, medication toxicity, or an unfamiliar environment.
Starting or increasing a psychiatric medicine without looking for these problems can delay treatment of the actual cause. If a normally cooperative person abruptly begins yelling and pushing caregivers while also refusing food and appearing drowsy, the priority is an urgent clinical assessment. Emergency help is appropriate when there is immediate danger, serious injury, inability to maintain safety, breathing difficulty, seizure activity, or a severe change in consciousness.
Frequently Asked Questions
Can Auvelity calm an aggressive episode immediately?
No. The FDA prescribing information states that Auvelity is not an as-needed treatment for Alzheimer’s agitation. An acute dangerous episode requires de-escalation, immediate safety measures, and evaluation for medical or environmental triggers.
When should caregivers first look for improvement?
Caregivers may notice changes during the first or second week, but the controlled evidence showed a clearer difference by week three and evaluated the main outcome at week five. Daily behavior records make gradual changes easier to detect.
What if there is no improvement after five weeks?
The prescriber should review adherence, the dose reached, adverse effects, the accuracy of the diagnosis, and unresolved triggers such as pain or constipation. The medication should not be increased beyond the prescribed maximum or stopped without clinical guidance.
Does Auvelity treat Alzheimer’s disease itself?
No. It treats agitation associated with dementia due to Alzheimer’s disease. It is not approved to improve memory, remove amyloid, or slow the underlying neurodegenerative process.
Can Auvelity be taken with cough medicine or another antidepressant?
Not without a medication review. Some cough products contain dextromethorphan, and several antidepressants can raise the risk of serotonin syndrome or other interactions. Products containing additional bupropion also require particular caution.
